Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis

INTRODUCTION: Immune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse events (FAEs) of ICI combination therapy in mRCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yao-Ning, Xie, Guang-Yu, Xiao, Li, Mo, Dun-Chang, Huang, Jian-Feng, Luo, Peng-Hui, Liang, Xiu-Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315618/
https://www.ncbi.nlm.nih.gov/pubmed/37404816
http://dx.doi.org/10.3389/fimmu.2023.1196793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315618/
https://www.ncbi.nlm.nih.gov/pubmed/37404816
http://dx.doi.org/10.3389/fimmu.2023.1196793

Ejemplares similares